Abstract

RNA methylation at the nitrogen sixth of adenosine (m6A, N6-methyladenosine) is the most abundant RNA modification which plays a crucial role in all RNA metabolic aspects. Recently, m6A modification has been assigned to mediate the biological processes of cancer cells, but their significance in HNSCC development is still poorly described. Thus, the main aim of this study was to globally quantify m6A modification by the mass spectrometry approach and determine the mRNA expression level of selected m6A RNA methyltransferase (METTL3), demethylase (FTO), and m6A readers (YTHDF2, YTHDC2) in 45 HNSCC patients and 4 cell lines (FaDu, Detroit 562, A-253 and SCC-15) using qPCR. In the results, we have not observed differences in the global amount of m6A modification and the mRNA level of the selected genes between the cancerous and paired-matched histopathologically unchanged tissues from 45 HNSCC patients. However, we have found a positive correlation between selected RNA methylation machinery genes expression and m6A abundance on total RNA and characterized the transcript level of those genes in the HNSCC cell lines. Moreover, the lack of global m6A differences between cancerous and histopathologically unchanged tissues suggests that m6A alterations in specific RNA sites may specifically influence HNSCC tumorigenesis.

Highlights

  • HNSCC arises from the epithelial membranes of the oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx [1]

  • Head and neck squamous cell carcinoma tissues and paired-matched histopathologically unchanged tissues were collected from 45 patients who underwent tumor surgical resection in the Department of Head and Neck Surgery, Poznan University of Medical

  • We have characterized the m6 A level in the HNSCC cell lines with mean values equaling: FaDu 0.099, Detroit 562

Read more

Summary

Introduction

HNSCC (head and neck squamous cell carcinoma) arises from the epithelial membranes of the oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx [1]. HNSCC is the eighth most common malignant cancer worldwide and its comprehensive treatment includes surgery, chemotherapy, and/or radiotherapy based on the tumor localization and clinical stage. The treatment response and clinical outcome of HNSCC patients can be different even in the same tumor localization and staging. This observation is an effect of the diverse genetic and epigenetic landscape of individual tumors, which leads to an imbalance of cellular pathways and disorders in the signaling cascade and immune system [3,4,5]. The description of molecular mechanisms and identification of prognostic biomarkers for HNSCC is crucial to develop novel targeted therapeutic strategies

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call